vs

Side-by-side financial comparison of Masco (MAS) and Steris (STE). Click either name above to swap in a different company.

Masco is the larger business by last-quarter revenue ($1.9B vs $1.5B, roughly 1.3× Steris). Steris runs the higher net margin — 12.9% vs 11.9%, a 1.0% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 6.5%). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs -4.2%).

Masco Corporation is an American manufacturer of products for the home improvement and new home construction markets. Comprising more than 20 companies, the Masco conglomerate operates nearly 60 manufacturing facilities in the United States and over 20 in other parts of the world. Since 1969 it trades on the NYSE. Under the leadership of Richard Manoogian, the company grew exponentially and subsequently joined the Fortune 500 list of largest U.S. corporations.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

MAS vs STE — Head-to-Head

Bigger by revenue
MAS
MAS
1.3× larger
MAS
$1.9B
$1.5B
STE
Growing faster (revenue YoY)
STE
STE
+2.7% gap
STE
9.2%
6.5%
MAS
Higher net margin
STE
STE
1.0% more per $
STE
12.9%
11.9%
MAS
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
-4.2%
MAS

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
MAS
MAS
STE
STE
Revenue
$1.9B
$1.5B
Net Profit
$228.0M
$192.9M
Gross Margin
35.8%
43.8%
Operating Margin
16.5%
18.3%
Net Margin
11.9%
12.9%
Revenue YoY
6.5%
9.2%
Net Profit YoY
14.5%
11.2%
EPS (diluted)
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MAS
MAS
STE
STE
Q1 26
$1.9B
Q4 25
$1.8B
$1.5B
Q3 25
$1.9B
$1.5B
Q2 25
$2.1B
$1.4B
Q1 25
$1.8B
$1.5B
Q4 24
$1.8B
$1.4B
Q3 24
$2.0B
$1.3B
Q2 24
$2.1B
$1.3B
Net Profit
MAS
MAS
STE
STE
Q1 26
$228.0M
Q4 25
$165.0M
$192.9M
Q3 25
$189.0M
$191.9M
Q2 25
$270.0M
$177.4M
Q1 25
$186.0M
$145.7M
Q4 24
$182.0M
$173.5M
Q3 24
$167.0M
$150.0M
Q2 24
$258.0M
$145.4M
Gross Margin
MAS
MAS
STE
STE
Q1 26
35.8%
Q4 25
33.9%
43.8%
Q3 25
34.2%
44.2%
Q2 25
37.6%
45.1%
Q1 25
35.8%
43.3%
Q4 24
34.8%
44.5%
Q3 24
36.6%
43.6%
Q2 24
37.5%
44.7%
Operating Margin
MAS
MAS
STE
STE
Q1 26
16.5%
Q4 25
13.8%
18.3%
Q3 25
15.8%
18.2%
Q2 25
20.1%
17.7%
Q1 25
15.9%
14.6%
Q4 24
15.9%
17.9%
Q3 24
18.0%
16.5%
Q2 24
19.0%
14.5%
Net Margin
MAS
MAS
STE
STE
Q1 26
11.9%
Q4 25
9.2%
12.9%
Q3 25
9.9%
13.1%
Q2 25
13.2%
12.8%
Q1 25
10.3%
9.8%
Q4 24
10.0%
12.7%
Q3 24
8.4%
11.3%
Q2 24
12.3%
11.4%
EPS (diluted)
MAS
MAS
STE
STE
Q1 26
Q4 25
$0.81
$1.96
Q3 25
$0.90
$1.94
Q2 25
$1.28
$1.79
Q1 25
$0.87
$1.48
Q4 24
$0.85
$1.75
Q3 24
$0.77
$1.51
Q2 24
$1.17
$1.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MAS
MAS
STE
STE
Cash + ST InvestmentsLiquidity on hand
$423.7M
Total DebtLower is stronger
$2.9B
$1.9B
Stockholders' EquityBook value
$27.0M
$7.2B
Total Assets
$5.2B
$10.6B
Debt / EquityLower = less leverage
109.07×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MAS
MAS
STE
STE
Q1 26
Q4 25
$647.0M
$423.7M
Q3 25
$559.0M
$319.2M
Q2 25
$390.0M
$279.7M
Q1 25
$377.0M
$171.7M
Q4 24
$634.0M
$155.2M
Q3 24
$646.0M
$172.2M
Q2 24
$398.0M
$198.3M
Total Debt
MAS
MAS
STE
STE
Q1 26
$2.9B
Q4 25
$2.9B
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.9B
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Stockholders' Equity
MAS
MAS
STE
STE
Q1 26
$27.0M
Q4 25
$-185.0M
$7.2B
Q3 25
$-78.0M
$7.0B
Q2 25
$-84.0M
$7.0B
Q1 25
$-254.0M
$6.6B
Q4 24
$-279.0M
$6.4B
Q3 24
$-88.0M
$6.6B
Q2 24
$-26.0M
$6.4B
Total Assets
MAS
MAS
STE
STE
Q1 26
$5.2B
Q4 25
$5.2B
$10.6B
Q3 25
$5.3B
$10.4B
Q2 25
$5.3B
$10.4B
Q1 25
$5.1B
$10.1B
Q4 24
$5.0B
$10.0B
Q3 24
$5.3B
$10.2B
Q2 24
$5.4B
$10.1B
Debt / Equity
MAS
MAS
STE
STE
Q1 26
109.07×
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MAS
MAS
STE
STE
Operating Cash FlowLast quarter
$298.2M
Free Cash FlowOCF − Capex
$199.5M
FCF MarginFCF / Revenue
13.3%
Capex IntensityCapex / Revenue
1.8%
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MAS
MAS
STE
STE
Q1 26
Q4 25
$418.0M
$298.2M
Q3 25
$456.0M
$287.8M
Q2 25
$306.0M
$420.0M
Q1 25
$-158.0M
$260.8M
Q4 24
$407.0M
$332.8M
Q3 24
$416.0M
$250.7M
Q2 24
$346.0M
$303.7M
Free Cash Flow
MAS
MAS
STE
STE
Q1 26
Q4 25
$371.0M
$199.5M
Q3 25
$415.0M
$201.3M
Q2 25
$270.0M
$326.4M
Q1 25
$-190.0M
$189.9M
Q4 24
$351.0M
$243.6M
Q3 24
$378.0M
$148.8M
Q2 24
$303.0M
$195.7M
FCF Margin
MAS
MAS
STE
STE
Q1 26
Q4 25
20.7%
13.3%
Q3 25
21.6%
13.8%
Q2 25
13.2%
23.5%
Q1 25
-10.5%
12.8%
Q4 24
19.2%
17.8%
Q3 24
19.1%
11.2%
Q2 24
14.5%
15.3%
Capex Intensity
MAS
MAS
STE
STE
Q1 26
1.8%
Q4 25
2.6%
6.6%
Q3 25
2.1%
5.9%
Q2 25
1.8%
6.7%
Q1 25
1.8%
4.8%
Q4 24
3.1%
6.5%
Q3 24
1.9%
7.7%
Q2 24
2.1%
8.4%
Cash Conversion
MAS
MAS
STE
STE
Q1 26
Q4 25
2.53×
1.55×
Q3 25
2.41×
1.50×
Q2 25
1.13×
2.37×
Q1 25
-0.85×
1.79×
Q4 24
2.24×
1.92×
Q3 24
2.49×
1.67×
Q2 24
1.34×
2.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MAS
MAS

Segment breakdown not available.

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons